Moomoo AI 已提取核心訊息
Connect Biopharma Holdings Limited announced on February 12, 2024, the appointment of James Zuie-chin Huang, M.B.A., as a new member of its Board of Directors. Huang brings over three decades of biotech experience to the table, having founded Panacea Venture and served in senior roles at various prestigious firms and companies, including Kleiner Perkins China, Vivo Ventures, and Anesiva, Inc. His previous board memberships include Casi Pharmaceuticals, Windtree Therapeutics, and Alaunos Therapeutics, and he currently serves on the board of Kindstar Globalgene Technology. Huang's educational background includes an M.B.A. from Stanford and a B.S. in chemical engineering from UC Berkeley. The Board has confirmed Huang as an independent director per Nasdaq's listing requirements, and he has entered into the company's standard Indemnification Agreement. There are no disclosed arrangements or transactions involving Huang that would necessitate disclosure under SEC regulations.
Connect Biopharma Holdings Limited announced on February 12, 2024, the appointment of James Zuie-chin Huang, M.B.A., as a new member of its Board of Directors. Huang brings over three decades of biotech experience to the table, having founded Panacea Venture and served in senior roles at various prestigious firms and companies, including Kleiner Perkins China, Vivo Ventures, and Anesiva, Inc. His previous board memberships include Casi Pharmaceuticals, Windtree Therapeutics, and Alaunos Therapeutics, and he currently serves on the board of Kindstar Globalgene Technology. Huang's educational background includes an M.B.A. from Stanford and a B.S. in chemical engineering from UC Berkeley. The Board has confirmed Huang as an independent director per Nasdaq's listing requirements, and he has entered into the company's standard Indemnification Agreement. There are no disclosed arrangements or transactions involving Huang that would necessitate disclosure under SEC regulations.
Connect Biopharma Holdings Limited於2024年2月12日宣佈，任命工商管理碩士黃瑞欽爲董事會新成員。黃擁有超過三十年的生物技術經驗，他創立了Panacea Venture，並在包括克萊納·珀金斯中國、Vivo Ventures和Anesiva公司在內的多家知名公司和公司擔任高級職務。他之前的董事會成員包括卡西製藥、Windtree Therapeutics和Alaunos Therapeutics，目前在Kindstar Globalgene Technology的董事會任職。黃的教育背景包括斯坦福大學的工商管理碩士學位和加州大學伯克利分校的化學工程學士學位。根據納斯達克的上市要求，董事會已確認黃爲獨立董事，他已經簽訂了公司的標準賠償協議。根據美國證券交易委員會的規定，沒有任何涉及黃的披露安排或交易需要披露。
Connect Biopharma Holdings Limited於2024年2月12日宣佈，任命工商管理碩士黃瑞欽爲董事會新成員。黃擁有超過三十年的生物技術經驗，他創立了Panacea Venture，並在包括克萊納·珀金斯中國、Vivo Ventures和Anesiva公司在內的多家知名公司和公司擔任高級職務。他之前的董事會成員包括卡西製藥、Windtree Therapeutics和Alaunos Therapeutics，目前在Kindstar Globalgene Technology的董事會任職。黃的教育背景包括斯坦福大學的工商管理碩士學位和加州大學伯克利分校的化學工程學士學位。根據納斯達克的上市要求，董事會已確認黃爲獨立董事，他已經簽訂了公司的標準賠償協議。根據美國證券交易委員會的規定，沒有任何涉及黃的披露安排或交易需要披露。
有用
沒用